Purpose: The aim of the study was to investigate the effect of autologous platelet-rich plasma (PRP) on the osteogenic potential of a biphasic synthetic graft material composed of hydroxyapatite and beta-tricalcium phosphate (HA/β-TCP) in critical-size cranial defects in rabbits.
Materials and Methods: Three circular bicortical critical-size cranial defects were created in each of 18 rabbits. The first of the defects was grafted with autologous PRP and HA/β-TCP, the second was grafted with HA/β-TCP without PRP, and the third was left unfilled as a negative control. Animals were euthanized at 2, 4, and 6 weeks after surgery. Harvested tissue specimens were evaluated histologically and histomorphometrically. Several parameters associated with osteoclastic and osteoblastic activities were measured and calculated. The results were statistically analyzed using the 1-way analysis of variance statistical method.
Results: Histologic analysis of the samples showed bone tissue formation at all experimental sites including untreated control defects. A statistically significant difference in new bone formation between the defects treated with HA/β-TCP + PRP and defects treated with HA/β-TCP alone was not observed. Control untreated defects showed the greatest bone regeneration.
Conclusions: In this animal model, autologous PRP had no effect on bone healing in addition to a biphasic HA/β-TCP synthetic graft material after 2, 4, and 6 weeks of implantation.
From the *Department of Oral and Maxillofacial Surgery, Faculty of Dentistry; †Department of Oral Medicine and Pathology, Faculty of Dentistry; ‡Laboratory for Research of the Musculoskeletal System “Th. Garofalidis,” Faculty of Medicine; and §Laboratory for Experimental Surgery and Surgical Research “N.S. Christeas,” Faculty of Medicine, University of Athens, Greece.
Received January 31, 2012.
Accepted for publication April 24, 2012.
Address correspondence and reprint requests to Dr Minas Leventis, 2 Thivon St, 11527, Athens, Greece; E-mail: email@example.com
The authors report no conflicts of interest.